Alisertib

DB05220InvestigationalSmall molecule

Alisertib is a novel aurora A kinase inhibitor under investigation for the treatment of various forms of cancer.

Mechanism: Pharmacologically active on Aurora kinase A
Curator reviewed
Primary indication: For the treatment of various forms of cancer.Curator reviewed
Formula / weight: C₂₇H₂₀ClFN₄O₄ · 518.93 g/mol (avg)
Code names: MLN-8237

Resolves to

Compound

Clinical / RWD

Structure

InChIKeyZLHFILGSQDJULK-UHFFFAOYSA-NSMILESCOC1=CC(NC2=NC=C3CN=C(C4=CC(Cl)=CC=C4C3=N2)C2=C(OC)C=CC=C2F)=CC=C1C(O)=O

Targets

What you can answer from here — as of September 12, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

63Clinical trialsPhase, status and sponsor resolved per trial

7+ReferencesStructured and connected to the statements they support

Which drugs share a target with Alisertib, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.